Badanie kliniczne nad trehalozą dihydratem w leczeniu ataksji rdzeniowo-móżdżkowej typu 3 u dorosłych

Spinocerebellar Ataxia type-3 (SCA3) is a condition that affects the brain and causes problems with movement and coordination. This study is looking at a new treatment called SLS-005, which is a solution given through a drip into a vein. The main ingredient in this treatment is called trehalose dihydrate. The study aims to see if this treatment can help adults with SCA3.

Participants in the study will receive either the SLS-005 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study is designed to be "double-blind," meaning neither the participants nor the researchers know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased. The study will last for about a year, and participants will be monitored to see how their symptoms change over time.

The goal of the study is to determine if SLS-005 can improve the symptoms of SCA3. Researchers will look at changes in movement and coordination, as well as any side effects that may occur. The study will help understand if this new treatment is safe and effective for people with SCA3.